Plasma biomarkers including glial fibrillary acidic protein (GFAP) and phosphorylated tau species (pTau181, pTau231, pTau217) now enable non-invasive assessment of AD pathology and neuroinflammation [6]. This evidence concerns the gene MAPT and Alzheimer disease.